Morgan Stanley Adc Therapeutics Sa Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Morgan Stanley holds 2,720,395 shares of ADCT stock, worth $8.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,720,395
Previous 781,937
247.9%
Holding current value
$8.6 Million
Previous $1.3 Million
840.99%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ADCT
# of Institutions
43Shares Held
36MCall Options Held
156KPut Options Held
55.9K-
Redmile Group, LLC San Francisco, CA15.3MShares$48.3 Million2.7% of portfolio
-
Prosight Management, LP Dallas, TX7.05MShares$22.3 Million9.1% of portfolio
-
Goldman Sachs Group Inc New York, NY1.54MShares$4.87 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.27MShares$4.01 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC1.19MShares$3.77 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $245M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...